Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899045 | 0.88 | LARS1 (0.52) | LARS1CYP19A1CYP2C9CYP2C19PDE3A | |
| SCHEMBL13898737 | 0.87 | LARS1 (0.51) | LARS1CYP19A1CYP2C9CYP2C19PDE3A | |
| SCHEMBL13898794 | 0.84 | LARS1 (0.69) | LARS1CYP19A1CYP2C9CYP2C19PDE3A | |
| SCHEMBL13898966 | 0.83 | LARS1 (0.49) | LARS1ALDH1A1TP53 | |
| SCHEMBL13899059 | 0.83 | LARS1 (0.56) | LARS1 | |
| SCHEMBL3914826 | 0.83 | LARS1 (0.70) | LARS1 | |
| SCHEMBL13898735 | 0.83 | CYP19A1 (0.47) | LARS1CYP19A1CYP2C9CYP2C19PDE3A | |
| SCHEMBL13898774 | 0.81 | LARS1 (0.49) | LARS1CYP2C9CYP2C19ALDH1A1TP53 | |
| SCHEMBL13898780 | 0.81 | LARS1 (0.49) | LARS1CYP19A1CYP2C9CYP2C19PDE3A | |
| SCHEMBL13898727 | 0.80 | LARS1 (0.47) | LARS1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049623-A1 | Imidazolidinone compounds | PKN2, PKN1, EIF2AK2 | LARS1 4511/4885CYP19A1 3424/4885CYP2C9 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.